In Memory of Mike Watson
We are so very sad to announce that Mike Watson unexpectedly passed away on Saturday 27 August 2022.
Mike was a fundamental part of the formation and success of our companies. He was Executive Chairman at VaxEquity, and co-founder and CEO of MEVOX. Over his long and distinguished career, working in the UK, France, and the USA, he made a significant impact on global vaccine R&D, clinical development, vaccine introduction and vaccination policy for diseases including HPV, polio, and influenza. He also thought beyond vaccines, exploring how novel technologies and platforms such as mRNA could be used therapeutically. His thinking and work had a significant impact on global public health. We are privileged to have worked alongside such an empathic, enthusiastic, and exceptional person. We will continue Mike’s inspiring work to improve human health all around the world.
Over 20 years of global vaccines experience from discovery through to policy launch and implementation in the UK, Europe, and USA with Sanofi Pasteur, Merck (MSD), Acambis and most recently building and leading Moderna’s infectious diseases and vaccines, venture.
As well as taking 8 vaccines to first in man, 3 to phase 2/3, and 3 to licensure, recommendation and launch, he has extensive experience with novel platforms & technologies, global vaccines (Gardasil/HPV, Polio, and Influenza) and national and global vaccination innovation (Pediacel, Dengvaxia, Polio and Influenza).
He is driven by the exceptional opportunity that vaccines give him to combine cutting-edge science, working with extraordinary people and impacting lives everywhere.
Chief Scientific Officer
With over 20 yrs of vaccine discovery and proven track record of structure-based vaccine design, has 70 peer-reviewed publications and 20 patents and patent applications spanning cancer, HIV-1, respiratory syncytial virus, parainfluenza virus, Nipah, metapneumovirus, measles, mumps and SARS-CoV-2 among other human and veterinary vaccines.
Co-inventor of a RSV preF vaccine, currently in Phase 2 clinical trials and of a SARS-CoV-2 vaccine with >100M doses administered in >48 countries.
Was head of the VRC/NIH Pathogen Response Unit, designed and discovered vaccines to emerging and re-emerging human pathogens and Associate Director of Antigen Design at Moderna. Previously Principal Investigator at Oxford University in virology, immunology and structural biology.